Avacta Group (OTCPK:AVCT.F) - Stock Price, News & Analysis

AVCT.F Stock Overview

Develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. More details

AVCT.F fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 2.1% per year for the next 3 years

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Avacta Group Plc Competitors

Mersana Therapeutics

NasdaqGS:MRSN

US$247.1m

Voyager Therapeutics

NasdaqGS:VYGR

US$314.1m

ProQR Therapeutics

NasdaqCM:PRQR

US$365.3m

Sutro Biopharma

NasdaqGM:STRO

US$215.2m

Price History & Performance

Summary of all time highs, changes and price drops for Avacta Group
Historical stock prices
Current Share Price	UK£0.65
52 Week High	UK£2.17
52 Week Low	UK£0.48
Beta	1.18
11 Month Change	-19.95%
3 Month Change	-29.45%
1 Year Change	-58.71%
33 Year Change	-55.62%
5 Year Change	n/a
Change since IPO	-54.88%

Recent updates

Shareholder Returns

	AVCT.F	US Biotechs	US Market
7D	0%	4.0%	2.2%
1Y	-58.7%	18.3%	32.6%

Return vs Industry: AVCT.F underperformed the US Biotechs industry which returned 18.3% over the past year.

Return vs Market: AVCT.F underperformed the US Market which returned 32.6% over the past year.

Price Volatility

Is AVCT.F's price volatile compared to industry and market?
AVCT.F volatility
AVCT.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AVCT.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AVCT.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2003	154	Chris Coughlin	www.avacta.com

Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets.

Avacta Group Plc Fundamentals Summary

How do Avacta Group's earnings and revenue compare to its market cap?
AVCT.F fundamental statistics
Market cap	US$229.57m
Earnings (TTM)	-US$32.48m
Revenue (TTM)	US$28.38m

8.1x

P/S Ratio

-7.1x

P/E Ratio

Is AVCT.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVCT.F income statement (TTM)
Revenue	UK£22.62m
Cost of Revenue	UK£13.10m
Gross Profit	UK£9.52m
Other Expenses	UK£35.40m
Earnings	-UK£25.89m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.071
Gross Margin	42.08%
Net Profit Margin	-114.45%
Debt/Equity Ratio	49.8%

How did AVCT.F perform over the long term?

See historical performance and comparison

AVCT.F Stock Overview

Risk Analysis

Avacta Group Plc Competitors

NasdaqGS:MRSN

US$247.1m

NasdaqGS:VYGR

US$314.1m

NasdaqCM:PRQR

US$365.3m

NasdaqGM:STRO

US$215.2m

Price History & Performance

Recent News & Updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Recent updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA

Avacta Group plc Announces Results of Initial Evaluation of Sars-Cov-2 Lateral Flow Antigen Test with Clinical Samples

Avacta Group plc Enters into Commercial Partnership with Mologic Ltd

Avacta Announces Collaboration Agreement with Bruker

Avacta Group plc Announces License Agreement with Point Biopharma Inc

Avacta Submits Clinical Trial Application for Ava6000 Pro-Doxorubixin

Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology

Avacta Group plc Announces Significant Progress in Development of a Highly Scalable Manufacturing Process for Lateral Flow SARS-CoV-2 Antigen Test

Avacta Group Plc Launches SARS-CoV-2 BAMS Research Test

Shareholder Returns